Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04573309 · ClinicalTrials.gov registry record · Phase 2
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04573309 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT04573309, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
Interventions
- DRUG ALXN1840
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-09-07 |
| Est. Completion | 2022-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04573309
The ClinicalTrials.gov registry entry for NCT04573309 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALXN1840 is the first listed.
NCT04573309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04573309 about?
NCT04573309 is a clinical study titled "Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840". This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
What is the current status of trial NCT04573309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-09-07. Estimated completion is 2022-06-07.
What interventions are being tested in trial NCT04573309?
The interventions under investigation include: ALXN1840 (DRUG).
Who is sponsoring clinical trial NCT04573309?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.